Now, it's all making sense.

According to The Daily Mail, a declassified CIA document is raising concerns that the agency purposely suppressed information that could have been a valuable tool in treating cancer:

A newly surfaced CIA document suggests US intelligence once reviewed research that hinted at a possible cancer treatment more than 60 years ago.

The document, produced in February 1951 and declassified in 2014, summarizes a Soviet scientific paper that examined striking similarities between parasitic worms and cancerous tumors.

The report describes how researchers believed both organisms thrived under nearly identical metabolic conditions and accumulated large reserves of glycogen, a form of stored energy.

Indeed, Soviet research regarding anti-parasticis and cancer at the time was showing promising results:

The research also highlighted experiments showing that certain chemical compounds were capable of targeting both parasitic infections and malignant tumors.

One drug, Myracyl D, was reportedly effective against bilharzia parasites as well as cancerous growths, hinting that treatments developed for parasites might also attack tumors.

According to Nicolas Hulscher with The McCullough Foundation:

"Instead of being used to advance critical cancer research, the document was buried for over half a century."

Recent Data Also Ignored

But there's more…

DON'T LET THE CIA CONTROL YOUR HEALTH

It's not just the results of these Soviet studies that were buried for decades by the CIA. The off-label use of antiparasitic drugs like ivermectin and mebendazole has demonstrated highly promising anticancer activity in preclinical models. But despite compelling preclinical data and documented safe use in cancer patients, robust clinical evidence evaluating the ivermectin–mebendazole combination in oncology remains limited.

This is Why The Wellness Company Conducted its own Study

Treating cancer is big business and one that makes the big pharmaceutical companies massive amounts of cash. In 2024 alone, cancer treatments generated at least $200 billion in worldwide sales for the pharmaceutical industry.

Given the massive profit motive, it shouldn't be surprising that big pharma has shown zero interest in low-cost cancer treatments.

This is exactly why Dr. Peter McCullough and a number of his colleagues at The Wellness Company have recently authored a first-of-its-kind study of the application of Ivermectin + Mebendazole in the treatment of cancer.

The results of this study are nothing short of groundbreaking.